ClinicalTrials.gg

Program

SHR-3167

A development code. Also written as “SHR-3167 Injection” and “SHR-3167 injection;glargine insulin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Oct 28, 20269 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine97 open or runningphase 3since Oct 28, 2026Aug 2, 2023Dec 2026phase 2 · NCT07472725
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-3167, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 2, 2023First study: phase 1 study in T2DMFirst studyNCT05996380 · 52 planned · China
  2. Nov 12, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06688123 · 275 enrolled · China
  3. Jun 5, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07018453 · 173 enrolled · China
  4. Jun 16, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07032688 · 55 planned · China
  5. Mar 11, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07472725 · 102 enrolled · China
  6. Mar 18, 2026Phase 1 study in Diabetes MellitusNCT07489482 · 60 planned · China
  7. May 8, 2026Phase 1 study in Healthy SubjectsNCT07588906 · 24 enrolled · China
  8. Oct 28, 20262 phase 3 studies in Diabetes Mellitus, Type 2Phase 3 reachedNCT07913061, NCT07920939

Ahead

  1. Dec 2026Primary completion: phase 1 study in Diabetes MellitusNCT07489482
  2. Dec 2026Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07472725
  3. Mar 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07032688
  4. Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07920939

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07920939Diabetes Mellitus, Type 2 · China3Not yet recruitingOct 2027450
NCT07913061Diabetes Mellitus, Type 2 · China3Not yet recruitingJan 2028680
NCT07588906Healthy Subjects · China1CompletedJul 12, 202424
NCT07489482Diabetes Mellitus · China1RecruitingDec 202660
NCT07472725Diabetes Mellitus, Type 2 · China2Active, not recruitingDec 2026102
NCT07032688Diabetes Mellitus, Type 2 · China1RecruitingMar 202755
NCT07018453Diabetes Mellitus, Type 2 · China2Active, not recruitingFeb 2026173
NCT06688123Diabetes Mellitus, Type 2 · China2CompletedApr 22, 2026275
NCT05996380T2DM · China1RecruitingJan 25, 202452

How it is read

Names in the registry

  • “SHR-3167”, 5 entries
  • “SHR-3167 Injection”, 4 entries
  • “SHR-3167 injection;glargine insulin”, 1 entry

Codes read as this program: SHR3167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.